Methods of using genetically engineered cells that produce insulin in response to glucose

• US 5,993,799 A
• Filed: 05/26/1995
• Issued: 11/30/1999
• Est. Priority Date: 02/20/1990
• Status: Expired due to Fees

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Newgard, Christopher R
• Primary Examiner(s): Campell, Bruce R.
• Assistant Examiner(s): Nguyen, Dave Trong
• Application Number:
  US08/452,334
• Time in Patent Office: 1,649 Days
• Field of Search: 210/192, 210/310, 435/240.2, 435/325, 435/455, 435/172.3, 435/320.1, 435/69.1, 435/6, 935/57, 935/62, 935/71, 421/93.21
• US Class Current: 424/93.21
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/62 Insulins
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 2310/111 spanning the whole gene, or a large part of it
• CPC Class Codes: C12N 9/1205 Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
• CPC Class Codes: C12Y 207/01001 Hexokinase (2.7.1.1)
• CPC Class Codes: G01N 2800/042 Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 33/50 Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 33/566 using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
• CPC Class Codes: G01N 33/567 utilising isolate of tissue or organ as binding agent
• CPC Class Codes: G01N 33/56966 Animal cells
• CPC Class Codes: G01N 33/66 involving blood sugars, e.g. galactose
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

The present disclosure relates to the application of genetic engineering to provide artificial β cells, i.e. cells which can secrete insulin in response to glucose. This is achieved preferably through the introduction of one or more genes selected from the insulin gene, glucokinase gene, and glucose transporter gene, so as to provide an engineered cell having all three of these genes in a biologically functional and responsive configuration. Assays for detecting the presence of diabetes-associated antibodies in biological samples using these and other engineered cells expressing diabetes-associated epitopes are described. Also disclosed are methods for the large-scale production of insulin by perfusing artificial β cells, grown in liquid culture, with glucose-containing buffers.

Claims

1. A method of providing glucose-responsive insulin secreting capability to a mammal comprising implanting into a mammal in need of insulin secreting capability a therapeutically effective amount of a cell population positioned in a selectively permeable membrane, said cell population comprising engineered cells that secrete insulin in response to glucose, the engineered cells comprising a gene encoding low affinity, high Km glucokinase (hexokinase IV), an insulin gene and a GLUT-2 glucose transporter gene, wherein at least one of said genes is a recombinant gene introduced into the cell by means of a recombinant vector.

2. The method of claim 1, wherein the cell population is implanted intraperitoneally or subcutaneously.

3. The method of claim 1, wherein the cell population is implanted within a selectively permeable device which is connected to the vasculature of the mammal.

4. The method of claim 1, wherein the cell population is positioned into a selectively permeable membrane within an implantable device.

5. The method of claim 4, wherein the selectively permeable membrane is further defined as a biocompatible coating.

6. The method of claim 5, wherein the cell population is encapsulated by the biocompatible coating.

7. The method of claim 6, wherein the biocompatible coating is a semipermeable capsule.

8. The method of claim 4, wherein the cell population is microencapsulated.

9. The method of claim 5, wherein the cell population is encapsulated in a hydrogel coating.

10. The method of claim 5, wherein the cell population is encapsulated in an alginate coating.

11. The method of claim 1, wherein the cell population is fiber seeded into a semipermeable fiber.

12. The method of claim 6, wherein about 1,000 to about 10,000 engineered cells are encapsulated within a semipermeable capsule or semipermeable fiber.

13. The method of claim 3, wherein the cell population is positioned in a tubular semipermeable membrane positioned within a protective housing.

14. The method of claim 13, wherein each end of said tubular membrane is attached to an arterial graft that extends beyond said housing and joins the device to a vascular system as a arteriovenous shunt.

15. The method of claim 1, wherein the GLUT-2 glucose transporter gene is a recombinant gene.

16. The method of claim 15, wherein the recombinant GLUT-2 glucose transporter gene is a cDNA.

17. The method of claim 1, wherein the cell population comprises engineered cells derived from a cell capable of forming secretory granules.

18. The method of claim 17, wherein the cell population comprises engineered cells derived from an endocrine cell.

19. The method of claim 18, wherein the cell population comprises engineered cells derived from a pituitary or thyroid cell.

20. The method of claim 19, wherein the cell population comprises engineered cells derived from AtT-20 cells.

21. The method of claim 17, wherein the cell population comprises engineered cells derived from GH-1 or GH-3 cells.

22. The method of claim 17, wherein the cell population comprises engineered cells derived from a β

cell.

23. The method of claim 22, wherein the cell population comprises engineered cells derived from β

TC, RIN or HIT cells.

24. The method of claim 1, wherein the cell population comprises engineered cells that secrete recombinant insulin.

25. The method of claim 1, wherein the cell population comprises an engineered cell that comprises a recombinant glutamic acid decarboxylase gene.

26. The method of claim 25, wherein the recombinant glutamic acid decarboxylase gene is a cDNA gene.

27. The method of claim 1, wherein the glucokinase gene is a recombinant glucokinase gene.

28. The method of claim 27, wherein the recombinant glucokinase gene is a cDNA.

29. The method of claim 27, wherein the recombinant glucokinase gene is an islet isoform of the glucokinase gene.

30. The method of claim 1, wherein the cell population comprises engineered cells that have a reduced hexokinase I activity relative to the cell from which they were prepared.

31. The method of claim 30, wherein the hexokinase I activity has been reduced by an antisense RNA molecule that is complementary to and capable of binding to an RNA transcript of a hexokinase gene.

32. The method of claim 30, wherein the hexokinase I activity has been reduced through the application of a positive/negative selection protocol.

33. The method of claim 1, wherein the cell population comprises a cell that secretes human insulin.

34. The method of claim 15, wherein the recombinant GLUT-2 glucose transporter gene is an islet isoform GLUT-2 gene.

35. The method of claim 1, wherein said mammal is a human.

36. The method of claim 20, wherein the cell population comprises CTG-5 or CTG-6 cells.